CONTACTStaffCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2023 Pride Publishing Inc.
All Rights reserved
All Rights reserved
Scroll To Top
By continuing to use our site, you agree to our Private Policy and Terms of Use.
CytRx Corp. has announced that an early-stage study of an HIV vaccine candidate has yielded positive results. Researchers at the University of Massachusetts Medical School and Advanced BioScience Laboratories developed the compound, DP6-001, which is based on DNA technology. The trial, which began in April 2004, showed the vaccine to be well-tolerated and effective at producing an immune response to HIV. The trial's 34 healthy volunteers were divided into groups according to how the compound was administered. Each group experienced positive results, whether the vaccine was administered three times a day under the skin or in muscle. Additional human trials are planned. (AP)
From our Sponsors
Most Popular
Watch Now: Advocate Channel
Trending Stories & News
For more news and videos on advocatechannel.com, click here.
Trending Stories & News
For more news and videos on advocatechannel.com, click here.
Latest Stories
Betches Media's Sami Sage on Reaching People Through Humor and Championing Women's Rights
March 03 2023 12:15 PM